A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2015
At a glance
- Drugs Tarloxotinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Proacta
- 22 Apr 2015 According to a Threshold Pharmaceuticals media release, data from this study were reported at the annual meeting of the American Association for Cancer Research (AACR) 2015.
- 13 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Mar 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.